Toshihiko Doi

36PUBLICATIONS
182CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsPharmacogenomicsMicrobial genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Sep 04, 2026
A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers.

|Aug 28, 2026
Potent antitumor efficacy of datopotamab deruxtecan compared with sacituzumab govitecan in an intracranial tumor model of triple-negative breast cancer.

|Mar 23, 2026
Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies.

Keun-Wook Lee, Elena Elimova, Do-Youn Oh

|Mar 01, 2026
Study protocol for a phase I investigator-initiated clinical trial of E7820 in Japanese patients with unresectable solid tumours: CIRCUS trial (NCCH2303).

Mao Okada, Jun Sato, Chikako Funasaka

|Dec 29, 2025
Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.

Shubham Pant, Joon Oh Park, Wu-Chou Su

|Nov 20, 2025
Pooled safety analysis of pimitespib for the treatment of patients with advanced gastrointestinal stromal tumors.

Yukinori Kurokawa, Noboru Yamamoto, Yuko Hirano

Pageof 6

Frequent Collaborators

4 joint publications

Yasutoshi Kuboki

4 joint publications

Kohei Shitara

3 joint publications

Hideaki Bando

3 joint publications

Hiroyoshi Nishikawa